Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.65 |
| ▸ | RAB9A | P51151 | 4/20 | 0.65 |
| ▸ | TP53 | P04637 | 3/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10174738 | 0.98 | KMT2A (0.66) | SMN1; SMN2NPC1RAB9ATP53RECQL | |
| SCHEMBL4486004 | 0.98 | KMT2A (0.66) | SMN1; SMN2NPC1RAB9ATP53RECQL | |
| SCHEMBL4480468 | 0.97 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ATP53RECQL | |
| SCHEMBL14234095 | 0.93 | ALDH1A1 (0.62) | SMN1; SMN2NPC1RAB9ATP53RECQL | |
| SCHEMBL13438861 | 0.88 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ATP53RECQL | |
| SCHEMBL13462850 | 0.86 | HPGD (0.53) | SMN1; SMN2NPC1RAB9ATP53RECQL | |
| SCHEMBL7901271 | 0.86 | RAB9A (0.67) | SMN1; SMN2NPC1RAB9ATP53RECQL | |
| SCHEMBL12333479 | 0.86 | MEN1 (0.61) | SMN1; SMN2NPC1RAB9ATP53RECQL | |
| SCHEMBL13462844 | 0.86 | PDE3B (0.53) | SMN1; SMN2NPC1RAB9ATP53RECQL | |
| SCHEMBL15986678 | 0.86 | SIGMAR1 (0.59) | SMN1; SMN2NPC1RAB9ATP53RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019154366-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏奥赛康药业有限公司 | 2019-08-15 | — | — | WO | disclosed |
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-05 | — | — | US | disclosed |
| US-9776969-B2 | Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides | AKEBIA THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9695182-B2 | Chemical compounds (derivatives) and their application for the treatment of oncological diseases | LIMITED LIABILITY COMPANY “NATIONAL PHARMACEUTICAL TECHNOLOGIES” (RU) | 2017-07-04 | — | — | US | disclosed |
| US-20160200729-A1 | NEW CHEMICAL COMPOUNDS (DERIVATIVES) AND THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES | LIMITED LIABILITY COMPANY (RU) | 2016-07-14 | — | — | US | disclosed |
| EP-2373634-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2015-11-11 | — | — | EP | disclosed |
| US-20120309977-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | AKEBIA THERAPEUTICS INC. (US) | 2012-12-06 | — | — | US | disclosed |
| WO-2010065717-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-06-10 | — | — | WO | disclosed |
| US-7429584-B2 | Furo[2.3-b]pyridine derivatives for the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1534715-B1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORP (US) | 2007-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170280720-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | SMN1; SMN2 1252/4885NPC1 631/4885RAB9A 1186/4885 |
| US-20160200729-A1 | NEW CHEMICAL COMPOUNDS (DERIVATIVES) AND THEIR APPLICATION FOR THE TREATMENT OF ONCOLOGICAL DISEASES | BRAF, CNKSR1, RAF1 | SMN1; SMN2 3750/4885NPC1 2017/4885RAB9A 662/4885 |
| US-20120309977-A1 | PROCESS FOR PREPARING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | HPD, APEH, ALDH7A1 | SMN1; SMN2 3805/4885NPC1 2528/4885RAB9A 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.